221 related articles for article (PubMed ID: 16204064)
1. Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival.
Tomicic MT; Christmann M; Kaina B
Cancer Res; 2005 Oct; 65(19):8920-6. PubMed ID: 16204064
[TBL] [Abstract][Full Text] [Related]
2. WRN protects against topo I but not topo II inhibitors by preventing DNA break formation.
Christmann M; Tomicic MT; Gestrich C; Roos WP; Bohr VA; Kaina B
DNA Repair (Amst); 2008 Dec; 7(12):1999-2009. PubMed ID: 18805512
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylation of p53 on Ser15 during cell cycle caused by Topo I and Topo II inhibitors in relation to ATM and Chk2 activation.
Zhao H; Traganos F; Darzynkiewicz Z
Cell Cycle; 2008 Oct; 7(19):3048-55. PubMed ID: 18802408
[TBL] [Abstract][Full Text] [Related]
4. Topotecan triggers apoptosis in p53-deficient cells by forcing degradation of XIAP and survivin thereby activating caspase-3-mediated Bid cleavage.
Tomicic MT; Christmann M; Kaina B
J Pharmacol Exp Ther; 2010 Jan; 332(1):316-25. PubMed ID: 19812371
[TBL] [Abstract][Full Text] [Related]
5. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.
Smith LM; Willmore E; Austin CA; Curtin NJ
Clin Cancer Res; 2005 Dec; 11(23):8449-57. PubMed ID: 16322308
[TBL] [Abstract][Full Text] [Related]
6. p53 dependence of topoisomerase I recruitment in vivo.
Mao Y; Okada S; Chang LS; Muller MT
Cancer Res; 2000 Aug; 60(16):4538-43. PubMed ID: 10969804
[TBL] [Abstract][Full Text] [Related]
7. Immunodetection of human topoisomerase I-DNA covalent complexes.
Patel AG; Flatten KS; Peterson KL; Beito TG; Schneider PA; Perkins AL; Harki DA; Kaufmann SH
Nucleic Acids Res; 2016 Apr; 44(6):2816-26. PubMed ID: 26917015
[TBL] [Abstract][Full Text] [Related]
8. Pifithrin-α enhancing anticancer effect of topotecan on p53-expressing cancer cells.
Guo J; Tang Q; Wang Q; Sun W; Pu Z; Wang J; Bao Y
Eur J Pharm Sci; 2019 Feb; 128():61-72. PubMed ID: 30472223
[TBL] [Abstract][Full Text] [Related]
9. Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis.
Bruzzese F; Rocco M; Castelli S; Di Gennaro E; Desideri A; Budillon A
Mol Cancer Ther; 2009 Nov; 8(11):3075-87. PubMed ID: 19887547
[TBL] [Abstract][Full Text] [Related]
10. Subnuclear distribution of DNA topoisomerase I and Bax protein in normal and xeroderma pigmentosum fibroblasts after irradiation with UV light and gamma rays or treatment with topotecan.
Thielmann HW; Popanda O; Staab HJ
J Cancer Res Clin Oncol; 1999; 125(3-4):193-208. PubMed ID: 10235474
[TBL] [Abstract][Full Text] [Related]
11. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Chen S; Gomez SP; McCarley D; Mainwaring MG
Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H
Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
[TBL] [Abstract][Full Text] [Related]
13. Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross-linking agent cisplatin.
Huang X; Okafuji M; Traganos F; Luther E; Holden E; Darzynkiewicz Z
Cytometry A; 2004 Apr; 58(2):99-110. PubMed ID: 15057963
[TBL] [Abstract][Full Text] [Related]
14. Assessment of ATM phosphorylation on Ser-1981 induced by DNA topoisomerase I and II inhibitors in relation to Ser-139-histone H2AX phosphorylation, cell cycle phase, and apoptosis.
Kurose A; Tanaka T; Huang X; Halicka HD; Traganos F; Dai W; Darzynkiewicz Z
Cytometry A; 2005 Nov; 68(1):1-9. PubMed ID: 16184611
[TBL] [Abstract][Full Text] [Related]
15. Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase I inhibitor or radiation.
Sabbatino F; Fusciello C; Somma D; Pacelli R; Poudel R; Pepin D; Leonardi A; Carlomagno C; Della Vittoria Scarpati G; Ferrone S; Pepe S
Cytometry A; 2014 Nov; 85(11):953-61. PubMed ID: 25182801
[TBL] [Abstract][Full Text] [Related]
16. Functional expression of human DNA topoisomerase I and its subcellular localization in HeLa cells.
Mo YY; Wang P; Beck WT
Exp Cell Res; 2000 May; 256(2):480-90. PubMed ID: 10772820
[TBL] [Abstract][Full Text] [Related]
17. [Effects of CPUY013, a novel Topo I inhibitor, on human gastric adenocarcinoma BGC823 cells in vitro and in vivo].
Ji YB; Zhou JH; Zuo MX; You QD
Yao Xue Xue Bao; 2008 Aug; 43(8):811-8. PubMed ID: 18956773
[TBL] [Abstract][Full Text] [Related]
18. Poly(ADPR)polymerase-1 signalling of the DNA damage induced by DNA topoisomerase I poison in D54(p53wt) and U251(p53mut) glioblastoma cell lines.
Cimmino G; Pepe S; Laus G; Chianese M; Prece D; Penitente R; Quesada P
Pharmacol Res; 2007 Jan; 55(1):49-56. PubMed ID: 17127074
[TBL] [Abstract][Full Text] [Related]
19. Cell cycle effects of topotecan alone and in combination with irradiation.
Ohneseit PA; Prager D; Kehlbach R; Rodemann HP
Radiother Oncol; 2005 May; 75(2):237-45. PubMed ID: 15890420
[TBL] [Abstract][Full Text] [Related]
20. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors.
Dubrez L; Goldwasser F; Genne P; Pommier Y; Solary E
Leukemia; 1995 Jun; 9(6):1013-24. PubMed ID: 7596166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]